Drug
S241656
S241656: highest development phase Phase 1/2, developed by Servier. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Servier
Trials
| Drug | Phase | Indication |
|---|---|---|
| S241656 NCT07719348 | Phase 1/2 | Acute Myeloid Leukemia |
| S241656 NCT05786924 | Phase 1/2 | Non-small Cell Lung Cancer |
Latest
No recent events.
Follow S241656 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.